Given that increased AMPK activity results in some side effects, such as cardiomyocyte hypertrophy, liver-specific activation of AMPK by liver cell-targeted drug delivery might be of great interest for the treatment of MASH. This evidence concerns the gene PRKAA1 and metabolic dysfunction-associated steatohepatitis.